Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride

被引:55
作者
Kivistö, KT
Lilja, TJ
Backman, JT
Neuvonen, PJ
机构
[1] Univ Helsinki, Dept Clin Pharmacol, FIN-00290 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland
关键词
D O I
10.1016/S0009-9236(99)70007-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Grapefruit juice increases the bioavailability of several drugs that are metabolized during first pass by CYP3A4, In this study, the effect of grapefruit juice on the pharmacokinetics of orally administered cisapride was investigated. Methods: In a randomized, two-phase crossover study, 10 healthy volunteers took either 200 mL double-strength grapefruit juice or water three times a day for 2 days. On day 3, each subject ingested 10 mg cisapride with either 200 mt grapefruit juice or water, and an additional 200 mt was ingested 1/2 hour and 11/2 hours after cisapride administration. Timed blood samples were collected for 32 hours after cisapride intake, and a standard 12-lead ECG was recorded before the administration of cisapride and 2, 5, 8, and 12 hours later. Results: The mean peak plasma concentration of cisapride was increased by 81% (range, 38% to 138%; P < .01) and the total area under the plasma cisapride concentration-time curve by 144% (range, 65% to 244%; P < .01) by grapefruit juice. The time of the peak concentration of cisapride was prolonged from 1.5 to 2.5 hours (P < .05) and the elimination half-life from 6.8 to 8.4 hours (P < .05) by grapefruit juice. ECG tracings did not show any significant differences in the QTc interval between the grapefruit juice and control phases. Conclusions: Grapefruit juice significantly increases plasma concentrations of cisapride, probably by inhibition of the CYP3A4-mediated first-pass metabolism of cisapride in. the small intestine. Concomitant use of high amounts of grapefruit juice and cisapride should be avoided, at least in patients with risk factors for cardiac arrhythmia.
引用
收藏
页码:448 / 453
页数:6
相关论文
共 26 条
[1]   Drug interactions with grapefruit juice [J].
Ameer, B ;
Weintraub, RA .
CLINICAL PHARMACOKINETICS, 1997, 33 (02) :103-121
[2]   GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN [J].
BAILEY, DG ;
ARNOLD, JMO ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :637-642
[3]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110
[4]   Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram [J].
Benton, RE ;
Honig, PK ;
Zamani, K ;
Cantilena, LR ;
Woosley, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) :383-388
[5]   LONG QT SYNDROME DURING HIGH-DOSE CISAPRIDE [J].
BRAN, S ;
MURRAY, WA ;
HIRSCH, IB ;
PALMER, JP .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (07) :765-768
[6]   The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice [J].
Clifford, CP ;
Adams, DA ;
Murray, S ;
Taylor, GW ;
Wilkins, MR ;
Boobis, AR ;
Davies, DS .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (04) :311-315
[7]   Identification and characterization of human cytochrome P450 (CYP) isoforms interacting with cisapride. [J].
Desta, Z ;
Thacker, D ;
Soukhova, N ;
Shin, JG ;
Flockhart, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) :126-126
[8]   Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval [J].
Drolet, B ;
Khalifa, M ;
Daleau, P ;
Hamelin, BA ;
Turgeon, J .
CIRCULATION, 1998, 97 (02) :204-210
[9]   DISPOSITION OF INTRAVENOUS AND ORAL CYCLOSPORINE AFTER ADMINISTRATION WITH GRAPEFRUIT JUICE [J].
DUCHARME, MP ;
WARBASSE, LH ;
EDWARDS, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (05) :485-491
[10]   Cisapride (CIS) biotransformation: Not all CYP3AS are created equal. [J].
Gotschall, RR ;
Marcucci, K ;
Leeder, JS ;
Kearns, GL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) :127-127